NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $59K rose 31.1% year over year, behind the +38.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at +190.2% a year.
Context
- Depreciation & amortization amounted to 1.0% of revenue in FY2025, up 0.7 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +31.1% toward the trailing-twelve-month pace of +38.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 220K USD
- Year-over-year change
- +94.7%
- 4-year CAGR
- +157.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 220K | +94.7% |
| FY2024 | 2024-12-31 | 113K | +130.6% |
| FY2023 | 2023-12-31 | 49K | +444.4% |
| FY2022 | 2022-12-31 | 9K | +80.0% |
| FY2021 | 2021-12-31 | 5K | — |
Depreciation & Amortization vs competitors
How NAMS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +38.6% is the 2nd highest of 9, against a peer median of +5.2%.
- Depreciation & amortization amounts to 3.4% of revenue for NAMS, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $13.14M USD | +17.5% | +12.6% | 364.7% | |
| LTM Jun 2026 | $1.52M USD | +7.1% | +47.7% | 0.1% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $1.25M USD | -21.5% | — | 1.3% |
| LTM Jun 2026 | $450K USD | +7.1% | +14.0% | — | |
| LTM Sep 2026 | $282K USD | -51.1% | +2.5% | — | |
| LTM Jun 2026 | $244K USD | +38.6% | +190.2% | 3.4% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K USD | +39.8% | +18.2% | 2.3% |
| LTM Mar 2026 | $185K USD | +3.4% | +2.9% | — | |
| FY2025 | A$28.31K AUD | -19.9% | -19.5% | 0.5% | |
| Peer median (excluding NAMS) | — | +5.2% | +12.6% | 1.3% | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 102.69M | 14.09M | 45.56M | 22.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 59K |
| Gross Profit | 0 | 102.69M | 14.09M | 45.56M | 22.44M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 99.7% |
| Research & Development | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M |
| Selling, General & Admin | 5.68M | 19.51M | 37.63M | 70.45M | 106.3M |
| Operating Expenses | 34.98M | 106.25M | 197.06M | 221.85M | 248.13M |
| Depreciation & Amortization | 5K | 9K | 49K | 113K | 220K |
| EBITDA | (41.37M) | (22.34M) | (176.86M) | (241.49M) | (242.33M) |
| EBITDA Margin | — | -21.8% | -1255.2% | -530.0% | -1076.9% |
| Operating Income | (34.98M) | (3.56M) | (182.97M) | (176.29M) | (225.68M) |
| Operating Margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Interest Income | 0 | 0 | 10.22M | 16.88M | 27.59M |
| Interest Expense | 411K | 287K | 6.8M | 0 | 0 |
| Other Income / Expenses | (6.81M) | (19.08M) | 6.06M | (65.31M) | 21.86M |
| Income Before Tax | (41.79M) | (22.63M) | (176.91M) | (241.6M) | (203.82M) |
| Pre-Tax Margin | — | -22.0% | -1255.6% | -530.3% | -905.7% |
| Income Tax Expense | 0 | 0 | 27K | (1K) | 0 |
| Net Income | (41.79M) | (22.63M) | (176.94M) | (241.6M) | (203.82M) |
| Net Margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
| EPS (Basic) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| EPS (Diluted) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| Weighted Avg Shares | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
| Weighted Avg Shares (Diluted) | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.